Beyond Addiction: A New Dawn for Pain Relief?

Groundbreaking study reveals investigational pain drug Cebranopadol shows significantly lower abuse potential, even when snorted, compared to notorious opioids like oxycodone.
This "first-in-class" dual-action compound could revolutionize pain management, offering potent relief without the devastating allure of addiction.
Tris Pharma is set to unveil these pivotal findings at the prestigious 2025 College on Problems of Drug Dependence (CPDD) Annual Meeting.

In a world reeling from the opioid crisis, a beacon of hope emerges. Tris Pharma has announced compelling data for Cebranopadol, an investigational pain treatment poised to rewrite the rules. At the upcoming CPDD Annual Meeting in New Orleans, the company will present positive results from a human abuse potential study, specifically focusing on intranasal (snorting) administration – a common and dangerous route of opioid misuse.

The findings are stark: Cebranopadol was "significantly less liked" when snorted compared to oxycodone⁷. This builds on earlier research showing its lower oral abuse potential than both oxycodone and tramadol. The secret lies in its novel mechanism: Cebranopadol targets both NOP and MOP receptors (a dual-NMR agonist), where NOP activation cleverly minimizes the euphoric, reinforcing effects typically driving MOP agonist abuse^{1, 2}.

"These results demonstrate the potential of Cebranopadol... to change how we treat pain while reducing the risk of misuse," stated Ketan Mehta, Tris Pharma's founder and CEO. Dr. Megan Shram, an expert in abuse potential studies, added that Cebranopadol "exhibits a distinct pharmacological profile" and "may offer an improved public health safety profile"⁴.

Currently in Phase III trials³, and backed by a NIDA grant for its potential in treating opioid use disorder, Cebranopadol isn't just about managing pain; it's about offering a lifeline, potentially breaking the cycle of addiction². If approved, it could become the first therapy providing opioid-like efficacy with a dramatically reduced shadow of misuse, dependence, and overdose. More information can be found at www.trispharma.com.

Beyond Addiction: A New Dawn for Pain Relief?

References

Stay Updated!